A phase I, pharmacokinetic (PK), and preliminary efficacy assessment of ALD518, a humanized anti-IL-6 antibody, in patients with advanced cancer

被引：0
|
作者：
Clarke, S. J. [1 ,2 ,3 ]
Smith, J. T. [1 ,2 ,3 ]
Gebbie, C. [1 ,2 ,3 ]
Sweeney, C. [1 ,2 ,3 ]
Olszewski, N. [1 ,2 ,3 ]
机构：
[1] Alder Biopharmaceut Inc, Bothell, WA USA
[2] Sydney Canc Ctr, Sydney, NSW, Australia
[3] Univ Adelaide, Adelaide, SA, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3025
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Preliminary results of a phase I study: A chimeric monoclonal anti IL-6 antibody CNTO 328 in combination with docetaxel in patients with hormone refractory prostate cancer
    Hudes, G. R.
    Nanus, D.
    Qi, M.
    Prabhakar, U.
    Corringham, R.
    Jiao, Q.
    Eisenberger, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [32] EFFICACY OF LEVILIMAB, NOVEL MONOCLONAL ANTI-IL-6 RECEPTOR ANTIBODY, IN COMBINATION WITH METHOTREXATE IN PATIENTS WITH RHEUMATOID ARTHRITIS: 1-YEAR RESULTS OF PHASE 2 AURORA STUDY
    Mazurov, V.
    Zotkin, E.
    Ilivanova, E.
    Kropotina, T.
    Plaksina, T.
    Nesmeyanova, O.
    Soroka, N.
    Kundzer, A.
    Lutskii, A.
    Dokukina, E.
    Eremeeva, A.
    Zinkina-Orihan, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 633 - 634
  • [33] Phase I safety, pharmacokinetic and pharmacodynamic study of recombinant human anti-VEGF antibody HuMV833 in patients with advanced cancer
    Mulatero, C
    Jayson, G
    Wagstaff, J
    Groenewegen, G
    Hakansson, L
    Ranson, M
    Levitt, D
    Tang, M
    Marréaud, S
    Zwierzina, H
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S80 - S80
  • [34] Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies
    Berger, Raanan
    Rotem-Yehudar, Rinat
    Slama, Gideon
    Landes, Shimon
    Kneller, Abraham
    Leiba, Merav
    Koren-Michowitz, Maya
    Shimoni, Avichai
    Nagler, Arnon
    CLINICAL CANCER RESEARCH, 2008, 14 (10) : 3044 - 3051
  • [35] Phase I pharmacokinetic, safety, and preliminary efficacy study of tiragolumab in combination with atezolizumab in Chinese patients with advanced solid tumors
    Shemesh, Colby S.
    Wang, Yongsheng
    An, Andrew
    Ding, Hao
    Chan, Phyllis
    Liu, Qi
    Chen, Yih-Wen
    Wu, Benjamin
    Wu, Qiong
    Wang, Xian
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2024, 94 (01) : 45 - 55
  • [36] Phase I and pharmacokinetic study of etaracizumab (Abegrin™), a humanized monoclonal antibody against αvβ3 integrin receptor, in patients with advanced solid tumors
    Catherine Delbaldo
    Eric Raymond
    Karina Vera
    Luz Hammershaimb
    Karen Kaucic
    Stéphanie Lozahic
    Michel Marty
    Sandrine Faivre
    Investigational New Drugs, 2008, 26 : 35 - 43
  • [37] Phase I and pharmacokinetic study of etaracizumab (Abegrin™), a humanized monoclonal antibody against αvβ3 integrin receptor, in patients with advanced solid tumors
    Delbaldo, Catherine
    Raymond, Eric
    Vera, Karina
    Hammershaimb, Luz
    Kaucic, Karen
    Lozahic, Stephanie
    Marty, Michel
    Faivre, Sandrine
    INVESTIGATIONAL NEW DRUGS, 2008, 26 (01) : 35 - 43
  • [38] A phase II multicenter study of CNTO 328, an anti-IL-6 monoclonal antibody, in patients (pts) with relapsed or refractory multiple myeloma (MM)
    Voorhees, P. M.
    Manges, R. F.
    Somlo, G.
    Lentzsch, S.
    Jagannath, S.
    Sonneveld, P.
    Frank, R. C.
    Zweegma, S.
    Wijermans, P. W.
    Thomas, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [39] A phase I and pharmacokinetic (PK) study of the novel mushroom-derived cytotoxin, MGI114, in patients with advanced cancer
    Eckhardt, SG
    Baker, SD
    Moczygemba, J
    MacDonald, JR
    Smith, S
    Von Hoff, DD
    Rowinsky, EK
    ANNALS OF ONCOLOGY, 1998, 9 : 123 - 123
  • [40] Phase I dose escalation and pharmacokinetic (PK) study of Pankomab in patients with TA-MUC1 positive advanced cancer
    Fiedler, W.
    Salzberg, M.
    Sessa, C.
    Cresta, S.
    de Dosso, S.
    Goletz, S.
    Gianni, L.
    ANNALS OF ONCOLOGY, 2011, 22 : 39 - 39
12345